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Background: We previously demonstrated remarkable differ-
ences in the expression of IL-8/CXCL8 in aortic tissues and 
vascular smooth muscle cells (VSMC) from spontaneously 
hypertensive rats (SHR) compared to VSMC from normo-
tensive Wistar-Kyoto rats (WKY). In the present study, we 
investigated the direct effect of IL-8/CXCL8 on expression 
of 12-lipoxygenase (LO), a hypertensive modulator, in SHR 
VSMC.  Methods: C u l t u r e d  a o r t i c  V S M C  f r o m  S H R  a n d  
WKY were used. Expression of 12-LO mRNA was de-
termined by real-time polymerase chain reaction. Phosphor-
lyation of ERK1/2 and production of 12-LO and angiotensin 
II subtype 1 (AT1) receptor were assessed by Western blots. 
IL-8/CXCL8-stimulated DNA synthesis was determined by 
measuring incorporation of [
3H]-thymidine. And effect of 
IL -8/C X C L8 on vascular tone w as determ ined by phenyl-
ephrine-induced contraction of thoracic aortic rings. Results: 
Treatment with IL-8/CXCL8 greatly increased 12-LO mRNA 
expression and protein production compared to treatment 
with angiotensin II. IL-8/CXCL8 also increased the ex-
pression of the AT1 receptor. The increase in 12-LO induced 
by IL-8/CXCL8 was inhibited by treatment with an AT1 re-
ceptor antagonist. The induction of 12-LO mRNA production 
and the proliferation of SHR VSMC by IL-8/CXCL8 was 
mediated by the ERK pathway. The proliferation of SHR 
VSMC and the vascular contraction in the thoracic aortic 
ring, both of which were induced by IL-8/CXCL8, were in-
hibited by baicalein, a 12-LO inhibitor. Conclusion: These re-
sults suggest that the potential role of IL-8/CXCL8 in hyper-
tensive processes is likely mediated through the 12-LO 
pathway.
[Immune Network 2009;9(3):106-113]
INTRODUCTION
Controlling chemokine production is important for regulating 
inflammatory reactions in hypertensive vascular walls. Inflam-
matory cell infiltration and oxidative stress in vascular walls 
contribute to the pathogenesis of hypertension, and the sup-
pression of inflammatory cell infiltration has been shown to 
ameliorate hypertension in experimental animal models (1-5). 
    The chemokine IL-8/CXCL8 has been known to play an im-
portant  role  in  monocyte  migration  into  the  subendothelial 
space in the early phase of atherosclerosis. In addition, ele-
vated levels of IL-8/CXCL8 are associated with an increased 
r i s k  o f  f u t u r e  c o r o n a r y  a r t e r y  d i s e a s e  ( 6 , 7 ) .  W e  h a v e  p r e -
viously  demonstrated  that  the  expression  of  IL-8/CXCL8  in 
aortic tissue and in vascular VSMC in SHR was higher than 
in  VSMC  from  normotensive  WKY  (8). 
    IL-8/CXCL8 was shown to increase 12-lipoxygenase (12-LO) 
mRNA  expression  and  protein  production  in  porcine  aortic 
VSMC (9). The 12-LO pathway of arachidonic acid metabo-
lism has been linked to cell growth and to the pathology of 
hypertension (10-12). Angiotensin II (Ang II) is a potent pos-
itive regulator of 12-LO activation and expression in porcine 
and human VSMC (13,14). Increased levels of 12-LO induced 
by cytokines in porcine VSMC and an elevated level of 12-LO 
activity in SHR plasma have been reported (9,15). However, 
neither the mechanism of IL-8/CXCL8 induction of 12-LO ex-
pression  nor  the  association  between  IL-8/CXCL8  and  the 
1 2 - L O  p a t h w a y  s p e c i f i c  t o  S H R  V S M C  h a v e  b e e n  s t u d i e d .  
Therefore,  we  investigated  the  mechanism  of  action  of Upregulation of 12-lipoxygenase by IL-8/CXCL8 
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IL-8/CXCL8  in  relation  to  the  expression  of  12-LO  in  SHR 
VSMC.
MATERIALS AND METHODS
Reagents
The Trizol reagent for total RNA isolation was purchased from 
Invitrogen (Carlsbad, CA). PBS, DMEM, penicillin-streptomycin 
and FBS were purchased from Gibco/BRL (Life Technologies, 
Gaithersburg,  MD).  Recombinant  human  IL-8/CXCL8  was 
purchased  from  R&D  systems  (Minneapolis,  MN).  Baicalein 
was obtained from Sigma Chemical Co. (St Louis, MO). Ang 
II was obtained from Calbiochem (San Diego, CA). 12-Hydro-
xyeicosatetraenoic acid (12-HETE) was purchased from Cayman 
Chemical (Ann Arbor, MI). Losartan was obtained from MSD 
(Delaware,  MD).  MAPK  inhibitor  and  2’-amino-3’ m e t h o x y -
flavone (PD98059) were purchased from Calbiochem. Nitro-
cellulose transfer membranes were obtained from Schleicher 
& Schuell Bioscience (Dassel, Germany). Oligonucleotide pri-
m er s f or  P CR of  1 2- LO ,  t h e AT 1 receptor,  the AT2 receptor 
and  β- a c t i n  w e r e  s y n t h e s i z e d  b y  B i o n i c s  ( S e o u l ,  K o r e a ) .  
L i g h t C y c l e r  F a s t S t a r t  D N A  S Y B R  G r e e n  I  M i x  w a s  o b t a i n e d 
from Roche (Mannheim, Germany). The 12-LO antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
The  AT1 r e c e p t o r  a n t i b o d y  w a s  p u r c h a s e d  f r o m  A b c a m  
(Cambridge, UK). The phospho-ERK antibody was obtained 
from Cell Signaling Technology (Danvers). The g-tubulin anti-
body was obtained from Sigma Chemical Co. (St Louis, MO). 
All  other  reagents  were  from  pure-grade  commercial 
preparations.
Experimental animals
Specific pathogen-free male inbred WKY and SHR, 20 to 30 
weeks of age, were purchased from Japan SLC Inc. (Shizuoka, 
Japan).  All  experimental  animals  received  autoclaved  food 
and  bedding  to  minimize  exposure  to  viral  and  microbial 
pathogens. The rats were cared for in accordance with the 
Guide  for  the  Care  and  Use  of  Experimental  Animals  of 
Yeungnam  Medical  Center.
VSMC preparation
VSMC were obtained by an explant method from the thoracic 
aortas of 20- to 30-week-old male SHR and WKY as described 
b y  K i m  e t  a l .  ( 8 ) .  V S M C  w e r e  c u l t u r e d  i n  D M E M  s u p p l e -
mented with 10% FBS and 1% penicillin-streptomycin. Cells 
were  detached  with  0.25%  trypsin/EDTA  and  seeded  into 
75-cm
2 tissue culture flasks at a density of 10
5 cells per milli-
liter. All experiments were conducted during cell passages 3 
to  7.  Prior  to  stimulation,  95%  confluent  VSMC  were  se-
rum-starved  overnight  by  incubating  in  DMEM  with  0.1% 
FBS. Cell cultures were incubated in a humidified incubator 
at  37
oC and 5% CO2  in  the  presence  or  absence  of  stimuli 
for  the  indicated  times. 
Preparation of total RNA and real-time PCR
Total RNA was extracted using the Trizol reagent according 
to the manufacturer’s instructions. The quantity of total RNA 
obtained  was  determined  by  measuring  the  optical  density 
(OD)  at  260  and  280  nm.  Real-time  PCR  amplification  of 
12-LO, the AT 1 receptor and the AT2 receptor from VSMC was 
performed using a LightCycler (Roche, Germany). cDNA was 
obtained by reverse transcription using 1μg of total RNA and 
then  subjected  to  real-time  PCR.  PCR  was  performed  in 
triplicate. Each 20-μl reaction contained LightCycler FastStart 
DNA SYBR Green I mix (Roche, Germany), primer and 2μl 
of  cDNA.  Prior  to  PCR  amplification,  the  mixture  was  in-
cubated  at  95
oC  for  10  min.  The  amplification  consisted  of 
45  cycles  of  denaturation  (10  s  at  95
oC ) ,  a n n e a l i n g  ( 5  s  a t 
the primer-appropriate temperature), and extension (10 s at 
72
oC)  with  fluorescence  detection  at  72
oC  after  each  cycle. 
After the  final cycle, melting point analysis of each sample 
was performed over the range of 65 to 95
oC with continuous 
fluorescence  detection.  Expression  levels  of  β-actin  were 
used for sample normalization. The results for each gene are 
expressed as the expression level relative to the expression 
level of β-actin. The primers used for PCR were as follows: 
12-LO  (312  bp)  sense,  5’-tggggcaactggaagg-3’,  antisense, 
5’-agagcgcttcagcaccat-3’;  AT1  receptor  (445  bp)  sense,  5’- 
cacctatgtaagatcgcttc-3’,  antisense,  5’-gcacaatcgccataattatcc-3’; 
AT2 receptor (65 bp) sense, 5’-ccgtgaccaagtcttgaagatg-3’, anti-
sense,  5’-agggaagccagcaaatgatg-3’;  β-actin  (101  bp)  sense, 
5’-tactgccctggctcctagca-3’,  antisense,  5’-tggacagtgaggccagga-
tag-3’.  The  levels  of  12-LO,  AT1  receptor  and  AT2 r e c e p t o r  
mRNA were determined by comparing experimental levels to 
standard curves. mRNA levels were expressed as the fold in-
crease  or  decrease  of  expression.
Western blotting
T o t a l  l y s a t e s  w e r e  p r e p a r e d  i n  P R O - P R E P  b u f f e r  ( i N t R O N ,  
Seoul, Korea). Protein concentrations were determined by a 
Bradford assay (Bio-Rad, CA) using bovine serum albumin as 
a  standard. Thirty  micrograms  of  the protein  samples were Upregulation of 12-lipoxygenase by IL-8/CXCL8 
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Figure 1. IL-8/CXCL8 increases 12-LO mRNA expre-
ssion and protein production in SHR VSMC. (A) SHR 
and WKY VSMC were isolated from the thoracic aorta
and cultured on plastic dishes at early passages (3 to 
7). Total RNA was analyzed by real-time PCR. Bars 
represent means±SD from three independent experi-
ments. *p＜0.05 vs. WKY VSMC. (B) WKY VSMC were
untreated or treated with IL-8/CXCL8 (100 ng/ml) for 2
h. Total RNA was then analyzed by real-time PCR. Bars
represent means±SD from three independent experi-
ments. (C) SHR VSMC were untreated or treated with 
IL-8/CXCL8 (100 ng/ml) or Ang II (100 nmol/L) for 2 
h. Total RNA was then analyzed by real-time PCR. Bars
represent means±SD from three independent experi-
ments. a: p＜0.05 vs. untreated VSMC. b: p＜0.05 vs. 
treated with IL-8/CXCL8. (D) SHR VSMC were un-
treated or treated with IL-8/CXCL8 (100 ng/ml) or Ang 
II (100 nmol/L) for 2 and 4 h. Cell lysates were sepa-
rated on 10% SDS-polyacrylamide gels and then immu-
noblotted with the 12-LO antibody. Data shown are 
representative of three independent experiments.
separated  on  10%  SDS-polyacrylamide  gels  and  then  trans-
ferred  to  nitrocellulose  membranes.  The  membranes  were 
soaked in 5% nonfat dried milk in TBST (10 mmol/L Tris-HCl 
pH 7.5, 150 mmol/L NaCl and 0.05% Tween-20) for 1 h and 
then incubated for 16∼18 h at 4
oC with primary antibodies 
against 12-LO, the AT1 receptor, phospho-ERK and γ-tubulin. 
The membranes were washed three times with TBST for 10 
min and then incubated with HRP-conjugated secondary anti-
body for 1 h at 4
oC. The membranes were rinsed three times 
with TBST for 10 min, and antigen-antibody complexes were 
detected  using  an  enhanced  chemiluminescence  detection 
system  (LAS-3000;  Fujifilm,  Tokyo,  Japan).
VSMC proliferation
VSMC were plated in 24-well plates for 24 h and then ex-
posed  to  the  stimulant.  [
3H]-thymidine  (1  μCi/ml)  (Perkin-
Elmer, Boston, MA) was added to the plates during the final 
48 h of incubation. The cells were subsequently washed three 
times  with  cold  PBS.  [
3H]-thymidine-labeled  cells  were  col-
lected with 0.1% SDS, and radioactivity was measured using 
a Packard scintillation counter (Packard instrument company, 
Meriden). 
Measurement of vascular tone
The thoracic aorta was cleared of adherent periadventitial fat 
and  cut into rings 3∼4 mm in  width.  To assess the  direct 
effects of IL-8/CXCL8 on the vascular smooth muscle, the en-
dothelium was removed by gently rubbing the lumenal sur-
face with a needle. The rings were mounted in an organ bath 
filled with Krebs solution (pH 7.4: in mmol/L: 118 NaCl, 4.7 
KCl,  2.5  CaCl2,  1.2  MgSO4,  1.2  KH2PO4,  5.7  glucose,  25 
NaHCO3) at 37
oC and 95% O2-5% CO2. Isometric force was 
measured with a force transducer (FT03, Grass Instrument). 
A tension of 1 g was applied, and the rings were equilibrated 
f o r  6 0  m i n .  D u r i n g  t h i s  p r o c e s s ,  t h e  K r e b s  s o l u t i o n  w a s  
changed every 15 min. The rings were then challenged with 
phenylephrine (PE, 10 μmol/L) to ensure tissue viability and 
with acetylcholine (Ach, 10 μmol/L) to ensure the absence 
of an endothelium. After inducing maximal contraction with 
the PE challenge, the vessels were incubated with IL-8/CXCL8 Upregulation of 12-lipoxygenase by IL-8/CXCL8 
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Figure 2. IL-8/CXCL8 increases AT1 receptor expression in SHR VSMC, and IL-8/CXCL8-induced expression of 12-LO mRNA is mediated through 
the AT1 receptor. (A) WKY and SHR VSMC were untreated or treated with IL-8/CXCL8 (100 ng/ml) for 2 h, and total RNA was analyzed by 
real-time PCR. Bars represent means±SD from four independent experiments. *p＜0.05 vs. untreated VSMC. (B) VSMC were untreated or treated 
with IL-8/CXCL8 (100 ng/ml) for 2 and 4 h. Cell lysates were separated on 10% SDS-polyacrylamide gels and then immunoblotted with the 
AT1 receptor antibody. Data shown are representative of three independent experiments. (C) VSMC were untreated or treated with IL-8/CXCL8 
(100 ng/ml) or IL-8/CXCL8 plus losartan (AT1 receptor antagonist, 10μmol/L) for 2 h or 4 h, and the total RNA and cell lysates were isolated. 
Total RNA was analyzed by real-time PCR. Cell lysates were separated on 10% SDS-polyacrylamide gels and then immunoblotted with the 12-LO
antibody. Bars represent means±SD from three independent experiments. *p＜0.05 vs. VSMC treated with IL-8/CXCL8. Data shown are 
representative of three independent experiments.
(200  ng/ml)  and  baicalein  (10  μm o l / L )  f o r  1  h .  A f t e r  i n -
cubation with IL-8/CXCL8 and baicalein, a cumulative phenyl-
ephrine dose-response curve was constructed (1∼100μmol/L).
Statistical analysis
The results are expressed as the mean±SD of at least three 
independent  experiments.  For  comparisons  among  multiple 
groups,  statistical  significance  was  determined  using  the 
Mann-Whitney  test  using  SPSS  version  12.0.
RESULTS
Effect of IL-8/CXCL8 on 12-LO in SHR VSMC 
We compared 12-LO expression in both SHR VSMC with the 
expression in and WKY VSMC. Expression of 12-LO mRNA 
was found to be higher in SHR VSMC relative to WKY VSMC 
(Fig. 1A). In addition, IL-8/CXCL8 treatment did not increase 
the expression level of 12-LO mRNA in WKY VSMC (Fig. 1B). 
We next examined the expression of 12-LO in SHR VSMC that 
had  been  treated  with  IL-8/CXCL8.  In  contrast,  IL-8/CXCL8 
treatment  in  SHR  VSMC  greatly  induced  the  expression  of 
12-LO mRNA compared to Ang II treatment (Fig. 1C). Large 
amounts of 12-LO protein were detected in SHR VSMC that 
h a d  b e e n  t r e a t e d  w i t h  I L - 8 / C X C L 8  f o r  4  h  ( F i g .  1 D ) .  
Effect of the AT1 receptor on IL-8/CXCL8-induced 
12-LO expression in SHR VSMC 
To determine whether IL-8/CXCL8-induced 12-LO production 
is mediated by the AT1 receptor, we first examined the effect 
of IL-8/CXCL8 on AT1 and AT2 receptor mRNA expression in 
WKY and SHR VSMC. IL-8/CXCL8 did not increase the ex-
pression of AT1 or AT 2 receptor mRNA in WKY VSMC (Fig. 
2A). However, treatment with IL-8/CXCL8 increased the ex-
pression of AT1 receptor mRNA in SHR VSMC (Fig. 2A). AT1 Upregulation of 12-lipoxygenase by IL-8/CXCL8 
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Figure 3. Expression of IL-8/CXCL8-induced 12-LO is mediated through the ERK pathway, and proliferation of SHR VSMC by IL-8/CXCL8 is 
inhibited by baicalein and PD98059. (A, B) VSMC were untreated (NT) or pretreated with PD98059 (ERK inhibitor, 10 μM) for 30 min. Cells 
were left untreated or treated with IL-8/CXCL8 (100 ng/ml) for 2 h, and the total RNA and cell lysates were isolated. The total RNA was analyzed 
by real-time PCR (A), and cell lysates were separated on 10% SDS-polyacrylamide gels and then immunoblotted with the phospho-ERK1/2 antibody 
(B). Bars represent means±SD from three independent experiments. *p＜0.05 vs. VSMC treated with IL-8/CXCL8. Data shown are representative 
of three independent experiments. (C, D) SHR VSMC were treated with 12-HETE (500 nmol/L), with IL-8/CXCL8 (100 ng/ml), with baicalein 
(12-LO inhibitor, 10 μmol/L, B), or with PD98059 (10 μmol/L, C) for 48 h in medium containing [
3H]-thymidine (1μCi/ml). [
3H]-thymidine 
incorporation is shown on the Y-axis. Bars represent means±SD from three independent experiments run in triplicate. *p＜0.05 vs. untreated 
VSMC. **p ＜0.01 vs. VSMC treated with IL-8/CXCL8 alone. a: p＜0.05 vs. VSMC treated with IL-8/CXCL8 alone.
Figure 4. Effect of IL-8/CXCL8 on the phenylephrine-induced contrac-
tion of thoracic aortic rings. Phenylephrine (1∼100  μmol/L) was 
added to isolated thoracic aortic rings pretreated with IL-8/CXCL8 (200
ng/mL) and/or the 12-LO inhibitor baicalein (10 μmol/L) for 1 h. All
contractions are expressed as grams (g) of contractile tension in control
rings not exposed to IL-8/CXCL8 or baicalein. Data are means±SD
of three independent experiments. a: p＜0.05 vs. control rings. b: p
＜0.05 vs. rings treated with IL-8/CXCL8 alone. 
receptor protein production was also detected in SHR VSMC 
(Fig. 2B). The AT1 receptor antagonist losartan (10 μmol/L) 
was  found  to  significantly  inhibit  IL-8/CXCL8-induced  ex-
pression of 12-LO mRNA. The production of the 12-LO pro-
tein was also inhibited by this antagonist (Fig. 2C). These re-
sults  suggest  that  the  induction  of  12-LO  expression  by 
IL-8/CXCL8 is mediated through the AT1 receptor expression 
i n  S H R  V S M C .   
IL-8/CXCL8-induced 12-LO expression is mediated 
by ERK phosphorylation 
We investigated whether the MAPK signaling pathway is in-
volved  in  IL-8/CXCL8-induced  12 - L O  e x p r e s s i o n .  T h e  I L - 8 /  
CXCL8-induced expression of 12-LO mRNA was decreased by 
PD98059  (Fig.  3A),  and  a  high  level  of  phosphorylation  of 
ERK in SHR VSMC treated with IL-8/CXCL8 was detected (Fig. 
3B)Upregulation of 12-lipoxygenase by IL-8/CXCL8 
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Effect of 12-LO and ERK activation on IL-8/CXCL8- 
induced VSMC proliferation
It has been reported that IL-8/CXCL8 induces rat and human 
VSMC proliferation (16). Having established that IL-8/CXCL8 
enhances  12-LO  expression  and  stimulates  VSMC  prolifera-
t i o n ,  w e  e v a l u a t e d  t h e  e f f e c t  o f  1 2 - H E T E ,  t h e  p r o d u c t  o f  
12-LO catalysis, on SHR VSMC proliferation. Fig. 3C shows 
that 12-HETE directly stimulates VSMC proliferation. In addi-
tion,  baicalein,  which  is  an  inhibitor  of  12-LO,  significantly 
inhibited the IL-8/CXCL8-induced proliferation of SHR VSMC. 
IL-8/CXCL8-induced  SHR  VSMC  proliferation  was  also  com-
pletely blocked by PD98059 (Fig. 3D). These results suggest 
that  ERK  and  12-LO  are  linked  in  the  IL-8/CXCL8-induced 
SHR  VSMC  proliferation  pathway. 
Effect of 12-LO on IL-8/CXCL8-induced vascular tone 
contraction
We also examined the potential role of 12-LO in mediating 
the vascular contraction effects of IL-8/CXCL8. This was done 
by  assessing  the  effect  of  10  μmol/L  baicalein  on  IL-8/ 
CXCL8-induced vascular contractions. The endothelium of the 
aortic  rings  was  removed  to  determine  the  direct  effect  of 
IL-8/CXCL8 on vascular smooth muscle. The force of vascular 
contractions  induced  by  IL-8/CXCL8  was  generated  greater 
than those of the control group. However, baicalein consid-
erably inhibited the contraction-inducing effect of IL-8/CXCL8 
(Fig.  4). 
DISCUSSION
AT1 receptor mediates most of pathophysiological actions of 
Ang II. Whereas stimulation of the AT1 receptor leads to acti-
vate  cytokines  and  adhesion  molecules  expression,  cell 
growth, angiogenesis and vasoconstriction, AT2 receptor stim-
ulation  causes  opposite  effects,  including  apoptosis,  anti-
angiogenesis,  and  vasodilatation  (17-19).  AT1 r e c e p t o r  i s  
widely  expressed  in  all  organs  and,  especially,  VSMC  ex-
presses AT1 receptors at ordinary times (20,21). In our study, 
we detected the expression of AT1 receptor mRNA in VSMC 
both of from SHR and WKY, however, the protein production 
of  AT1  receptor  was  very  weak  in  SHR  VSMC  (Fig.  1). 
IL-8/CXCL-8 increased AT1 receptor mRNA expression in SHR 
VSMC only, and confirmed strong production of AT1 receptor 
protein (Fig. 2B). Therefore, we observed the effects of AT1 
receptor  antagonists  on  IL-8/CXCL8-induced  12-LO  pro-
duction  in  SHR  VSMC.  AT1  receptor  antagonist  significantly 
inhibited  IL-8/CXCL8-induced  12-LO  production  (Fig.  2C). 
These results suggest that the action of IL-8/CXCL8 on hyper-
tensive  vasculature  is  likely  to  be  associated  with  the  AT1 
receptor. 
    ERK pathway was involved in IL-8/CXCL8-induced 12-LO 
expression in SHR VSMC. The IL-8/CXCL8-induced expression 
of 12-LO mRNA was decreased remarkably by PD98059, an in-
hibitor of ERK (Fig. 3A). We also examined whether p38 signal-
ing  pathway  is  involved  in  IL-8/CXCL8-induced  12-LO  ex-
pression in SHR VSMC. PD169316, an inhibitor of p38, also 
decreased  the  expression  of  IL-8/CXCL8-induced  12-LO 
mRNA in SHR VSMC. However, it did not inhibit significantly 
IL-8/CXCL8-induced  12-LO  mRNA  expression  compared  to 
PD98059  (data  not  shown). 
  IL-8/CXCL8 has been shown to have mitogenic effects on 
VSMC (16), and Natarajan et al. (9) reported that 12-LO in-
hibition  decreased  IL-8/CXCL8-induced  proliferation  in  por-
cine  VSMC.  We  also  found  that  baicalein  inhibited  IL-8/ 
CXCL8-induced  proliferation  of  SHR  VSMC  and  that  SHR 
VSMC proliferation induced by IL-8/CXCL8 was greater than 
Ang II-induced proliferation (data not shown). ERK activation 
has  been  demonstrated  in  the  normal  growth  of  mesangial 
cells and pulmonary artery smooth muscle cells in association 
with  the  stimulation  of  the  12-LO  pathway  (10,22).  In  this 
study,  IL-8/CXCL8-induced  12-LO  expression  was  mediated 
through  ERK  activation.  In  addition,  IL-8/CXCL8-induced 
VSMC  proliferation  was  completely  blocked  by  PD98059. 
These  results  suggest  that  ERK  activation  and  12-LO  ex-
pression are linked in IL-8/CXCL8-induced VSMC proliferation 
and  that  12-LO  induction  precedes  ERK  activation.
    Buemi et al. (23) suggested that IL-8/CXCL8 may directly 
enhance membrane permeability to Ca
2+, thus inducing vaso-
constriction in the smooth muscle cells of patients with essen-
tial hypertension. However, Ohkawa et al. (24) reported that 
IL-8/CXCL8  had  no  significant  effect  on  the  vascular  con-
traction of the thoracic aorta in Sprague-Dawley rats. In the 
present study, we observed a significant increase in the con-
traction of the thoracic aortic rings from SHR that were treated 
with IL-8/CXCL8, and this contraction decreased after baica-
lein treatment (Fig. 4). This result suggests that IL-8/CXCL8 
acts  on  vascular  contraction  through  the  12-LO  pathway  in 
SHR.
    This study demonstrates that IL-8/CXCL8-induced 12-LO ex-
pression is mediated through the AT1 receptor in SHR VSMC 
and that the 12-LO pathway participates in IL-8/CXCL8-induced Upregulation of 12-lipoxygenase by IL-8/CXCL8 
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S H R  V S M C  p r o l i f e r a t i o n ,  m o s t  l i k e l y  v i a  t h e  E R K  p a t h w a y .  
Taken together, our results suggest that the effect of IL-8/CXCL8 
on hypertensive vascular walls is mediated by the induction 
of  the  12-LO  pathway. 
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